View Author
patient hepatitis hbsag hepatitis b response treatment peg-ifn therapy study level decline hbeag serum peginterferon genotype hbeag-negative hbv dna baseline hbsag decline hepatology hbv dna levels peginterferon alfa -2a hbeag-positive liver hbeag-negative patients group virus hbeag loss hbsag levels combination peg-ifn therapy follow-up disease hbv genotype responder antigen hbeag-positive patients serum hbsag result trial university gastroenterology serum hbsag levels prediction week 12 on-treatment lamivudine hepatol hepatitis b virus 24 weeks monotherapy hepatitis b patients interferon analysis hbsag loss lau gk serum hbv dna piratvisuth t assay table ribavirin combination therapy surface 48 weeks month hbeag-negative chb population hbv dna decline treatment discontinuation value combination therapy group ltfu study netherland week 78 article off-treatment cakaloglu y rijckborst response rates phase
10 Most Recent Publications
|
Identification and treatment of chronic hepatitis B in Chinese migrants: Results of a project offering on-site testing in Rotterdam, the Netherlands
(Article)
Veldhuizen, I.K. Wolter, R. Rijckborst, V. Mostert, M.C. Voeten, H.A.C.M. Cheung, Y.M. Boucher, C.A.B. Reijnders, J.G.P. Zwart, O. de Janssen, H.L.A. |
2012-12-01
|
|
Long-term follow-up of hepatitis B e antigen-negative patients treated with peginterferon α-2a: Progressive decrease in hepatitis B surface antigen in responders
(Article)
Rijckborst, V. Ferenci, P. Vuuren, A.J. van Boucher, C.A.B. Hansen, B.E. Janssen, H.L.A. Akdogan, M. Pinarbasi, B. Borg, M.J. ter Simon, K. Flisiak, R. Akarca, U.S. Raptopoulou-Gigi, M. Verhey, E. |
2012-09-01
|
|
Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B
(Article)
Sonneveld, M.J. Rijckborst, V. Zeuzem, S. Heathcote, E.J. Simon, K. Senturk, H. Pas, S.D. Hansen, B.E. Janssen, H.L.A. |
2012-07-01
|
|
Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: Relation to response and HBV genotype
(Article)
Sonneveld, M.J. Rijckborst, V. Janssen, H.L.A. Cakaloglu, Y. Simon, K. Heathcote, E.J. Tabak, F. Mach, T. Boucher, C.A.B. Hansen, B.E. Zeuzem, S. |
2012-01-30
|
|
HBV DNA suppression in HBeAg-positive chronic hepatitis B patients treated with peginterferon or placebo
(Article)
Hansen, B.E. Rijckborst, V. Borg, M.J. ter Janssen, H.L.A. |
2011-11-01
|
|
A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B
(Article)
Sonneveld, M.J. Rijckborst, V. Boucher, C.A.B. Zwang, L. Beersma, M.F.C. Hansen, B.E. Janssen, H.L.A. |
2011-07-01
|
|
Prediction of Response to Immune Modifying Therapy for Patients with Chronic Hepatitis B using Hepatitis B Surface Antigen Levels
(Doctoral Thesis)
Rijckborst, V. |
2011-06-23
|
|
Review article: Chronic hepatitis B - Anti-viral or immunomodulatory therapy?
(Article)
Rijckborst, V. Sonneveld, M.J. Janssen, H.L.A. |
2011-03-01
|
|
Reply
(Article)
Sonneveld, M.J. Rijckborst, V. Janssen, H.L.A. |
2011-03-01
|
|
The role of interferon in hepatitis B therapy
(Article)
Rijckborst, V. Janssen, H.L.A. |
2010-11-01
|
